These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 23722548)
1. Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors. Zhou H; Hittelman WN; Yagita H; Cheung LH; Martin SS; Winkles JA; Rosenblum MG Cancer Res; 2013 Jul; 73(14):4439-50. PubMed ID: 23722548 [TBL] [Abstract][Full Text] [Related]
2. The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment. Zhou H; Ekmekcioglu S; Marks JW; Mohamedali KA; Asrani K; Phillips KK; Brown SA; Cheng E; Weiss MB; Hittelman WN; Tran NL; Yagita H; Winkles JA; Rosenblum MG J Invest Dermatol; 2013 Apr; 133(4):1052-62. PubMed ID: 23190886 [TBL] [Abstract][Full Text] [Related]
3. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies. Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850 [TBL] [Abstract][Full Text] [Related]
4. Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells. Zhou H; Marks JW; Hittelman WN; Yagita H; Cheung LH; Rosenblum MG; Winkles JA Mol Cancer Ther; 2011 Jul; 10(7):1276-88. PubMed ID: 21586630 [TBL] [Abstract][Full Text] [Related]
5. Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC. Zhou H; Mohamedali KA; Gonzalez-Angulo AM; Cao Y; Migliorini M; Cheung LH; LoBello J; Lei X; Qi Y; Hittelman WN; Winkles JA; Tran NL; Rosenblum MG Mol Cancer Ther; 2014 Nov; 13(11):2688-705. PubMed ID: 25239934 [TBL] [Abstract][Full Text] [Related]
7. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells. Huang J; Wang S; Lyu H; Cai B; Yang X; Wang J; Liu B Mol Cancer; 2013 Nov; 12(1):134. PubMed ID: 24215614 [TBL] [Abstract][Full Text] [Related]
8. The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Willis AL; Tran NL; Chatigny JM; Charlton N; Vu H; Brown SA; Black MA; McDonough WS; Fortin SP; Niska JR; Winkles JA; Cunliffe HE Mol Cancer Res; 2008 May; 6(5):725-34. PubMed ID: 18505918 [TBL] [Abstract][Full Text] [Related]
9. Development of an Fn14 agonistic antibody as an anti-tumor agent. Michaelson JS; Amatucci A; Kelly R; Su L; Garber E; Day ES; Berquist L; Cho S; Li Y; Parr M; Wille L; Schneider P; Wortham K; Burkly LC; Hsu YM; Joseph IB MAbs; 2011; 3(4):362-75. PubMed ID: 21697654 [TBL] [Abstract][Full Text] [Related]
10. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. Garrett JT; Sutton CR; Kurupi R; Bialucha CU; Ettenberg SA; Collins SD; Sheng Q; Wallweber J; Defazio-Eli L; Arteaga CL Cancer Res; 2013 Oct; 73(19):6013-23. PubMed ID: 23918797 [TBL] [Abstract][Full Text] [Related]
11. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Menendez JA; Vellon L; Lupu R Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086 [TBL] [Abstract][Full Text] [Related]
12. The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models. Michaelson JS; Kelly R; Yang L; Zhang X; Wortham K; Joseph IB Cancer Biol Ther; 2012 Jul; 13(9):812-21. PubMed ID: 22669574 [TBL] [Abstract][Full Text] [Related]
13. Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. Chao DT; Su M; Tanlimco S; Sho M; Choi D; Fox M; Ye S; Hsi ED; Durkin L; Yin J; Zhang Y; Kim H; Starling GC; Culp PA J Cancer Res Clin Oncol; 2013 Feb; 139(2):315-25. PubMed ID: 23073510 [TBL] [Abstract][Full Text] [Related]
14. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies. Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334 [TBL] [Abstract][Full Text] [Related]
15. Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells. Roos A; Dhruv HD; Mathews IT; Inge LJ; Tuncali S; Hartman LK; Chow D; Millard N; Yin HH; Kloss J; Loftus JC; Winkles JA; Berens ME; Tran NL Oncotarget; 2017 Feb; 8(7):12234-12246. PubMed ID: 28103571 [TBL] [Abstract][Full Text] [Related]
16. The HER2- and heregulin β1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression. Asrani K; Keri RA; Galisteo R; Brown SA; Morgan SJ; Ghosh A; Tran NL; Winkles JA Mol Cancer Res; 2013 Apr; 11(4):393-404. PubMed ID: 23378579 [TBL] [Abstract][Full Text] [Related]
17. Superior antitumor activity of a novel bispecific antibody cotargeting human epidermal growth factor receptor 2 and type I insulin-like growth factor receptor. Chen C; Zhang Y; Zhang Y; Li J; Tsao SW; Zhang MY Mol Cancer Ther; 2014 Jan; 13(1):90-100. PubMed ID: 24227890 [TBL] [Abstract][Full Text] [Related]
18. The TWEAK Receptor Fn14 Is an Src-Inducible Protein and a Positive Regulator of Src-Driven Cell Invasion. Cheng E; Whitsett TG; Tran NL; Winkles JA Mol Cancer Res; 2015 Mar; 13(3):575-83. PubMed ID: 25392346 [TBL] [Abstract][Full Text] [Related]
19. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Garrett JT; Sutton CR; Kuba MG; Cook RS; Arteaga CL Clin Cancer Res; 2013 Feb; 19(3):610-9. PubMed ID: 23224399 [TBL] [Abstract][Full Text] [Related]
20. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Raina D; Uchida Y; Kharbanda A; Rajabi H; Panchamoorthy G; Jin C; Kharbanda S; Scaltriti M; Baselga J; Kufe D Oncogene; 2014 Jun; 33(26):3422-31. PubMed ID: 23912457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]